Prostate cancer vaccines

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765 - 81; http://dx.doi.org/10.1016/j.ejca.2009.12.014; PMID: 20116997
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65:1180 - 92; http://dx.doi.org/10.1111/j.1742-1241.2011.02799.x; PMID: 21995694
   PubMed Web of Science ®Google Scholar
• Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73:1104 - 9; http://dx.doi.org/10.1016/j.urology.2008.07.062; PMID: 19394511
   PubMed Web of Science ®Google Scholar
• Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918 - 25; http://dx.doi.org/10.1200/JCO.2005.01.529; PMID: 15860850
   PubMed Web of Science ®Google Scholar
• Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 2011; 60:279 - 90; http://dx.doi.org/10.1016/j.eururo.2011.04.038; PMID: 21592649
   PubMed Web of Science ®Google Scholar
• Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics--theory. Urology 1981; 17:Suppl 3 40 - 53; PMID: 7010755
   PubMed Web of Science ®Google Scholar
• Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, et al. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008; 53:694 - 708; http://dx.doi.org/10.1016/j.eururo.2007.11.043; PMID: 18061335
   PubMed Web of Science ®Google Scholar
• Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175 - 82; PMID: 10873066
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894 - 903; PMID: 11099318
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670 - 9; http://dx.doi.org/10.1002/cncr.24429; PMID: 19536890
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61:639 - 47; http://dx.doi.org/10.1016/j.eururo.2011.10.027; PMID: 22036643
   PubMed Web of Science ®Google Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10:580 - 93; http://dx.doi.org/10.1038/nri2817; PMID: 20651745
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol 2013; 10:149 - 60; http://dx.doi.org/10.1038/nrurol.2013.8; PMID: 23399727
   PubMed Web of Science ®Google Scholar
• Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:273 - 9; http://dx.doi.org/10.1093/jnci/djr514; PMID: 22232132
   PubMed Web of Science ®Google Scholar
• Drake CG. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1422 - , author reply 1422-3; http://dx.doi.org/10.1093/jnci/djs340; PMID: 22911668
   PubMed Web of Science ®Google Scholar
• Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1106 - , author reply 1109-12; http://dx.doi.org/10.1093/jnci/djs280; PMID: 22825555
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178:1515 - 20; http://dx.doi.org/10.1016/j.juro.2007.05.117; PMID: 17707059
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4:1; http://dx.doi.org/10.1186/1479-5876-4-1; PMID: 16390546
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099 - 105; http://dx.doi.org/10.1200/JCO.2009.25.0597; PMID: 20100959
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663 - 74; http://dx.doi.org/10.1007/s00262-009-0782-8; PMID: 19890632
   PubMed Web of Science ®Google Scholar
• Higano C, Saad F, Somer B, Curti B, Petrylak DP, Drake CG, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol, 2009:Abstract # LBA150.
   Google Scholar
• Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12:1260 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-05-2059; PMID: 16489082
   PubMed Web of Science ®Google Scholar
• Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15:7375 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-09-1910; PMID: 19920098
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, et al. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:3883 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-06-2937; PMID: 17606721
   PubMed Web of Science ®Google Scholar
• Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113:975 - 84; http://dx.doi.org/10.1002/cncr.23669; PMID: 18646045
   PubMed Web of Science ®Google Scholar
• Small EJDT, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). 2009 Genitourinary Cancers Symposium (ASCO Annual Meeting Abstracts)2009:LBA150.
   Google Scholar
• van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509 - 17; http://dx.doi.org/10.1016/S1470-2045(12)70007-4; PMID: 22326922
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047 - 54; http://dx.doi.org/10.1200/JCO.2008.19.9968; PMID: 19636017
   PubMed Web of Science ®Google Scholar
• Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91:688 - 94; PMID: 15280930
   PubMed Web of Science ®Google Scholar
• Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10:1239 - 49; http://dx.doi.org/10.1089/10430349950018229; PMID: 10340555
   PubMed Web of Science ®Google Scholar
• Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12:1955 - 67; http://dx.doi.org/10.1089/104303401753204535; PMID: 11686937
   PubMed Web of Science ®Google Scholar
• Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13:716 - 28; http://dx.doi.org/10.1016/j.ymthe.2005.11.022; PMID: 16480930
   PubMed Web of Science ®Google Scholar
• Fong L, Weinberg VK, Corman JM, Amling CL, Stephenson RA, Formaker C, et al. Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer. 2012 Genitiurinary Cancers Symposium. J Clin Oncol2012.
   Google Scholar
• Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010; 16:304 - 10; http://dx.doi.org/10.1097/PPO.0b013e3181eb33d7; PMID: 20693840
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509 - 17; http://dx.doi.org/10.1016/S1470-2045(12)70007-4; PMID: 22326922
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355 - 66; http://dx.doi.org/10.1084/jem.190.3.355; PMID: 10430624
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95:10067 - 71; http://dx.doi.org/10.1073/pnas.95.17.10067; PMID: 9707601
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Small E, Demkow T, Gerritsen W, Rolland F, Hoskin P, Smith D, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol2009:Abstract #7.
   Google Scholar
• Drake CG. Immunotherapy for prostate cancer: walk, don’t run. J Clin Oncol 2009; 27:4035 - 7; http://dx.doi.org/10.1200/JCO.2009.22.2299; PMID: 19635998
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122 - 32; http://dx.doi.org/10.1200/JCO.2004.08.083; PMID: 15169798
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53:109 - 17; http://dx.doi.org/10.1002/pros.10130; PMID: 12242725
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232 - 7; http://dx.doi.org/10.1200/JCO.2003.06.100; PMID: 12663709
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150 - 7; http://dx.doi.org/10.3747/co.v18i3.783; PMID: 21655153
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, et al. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. Genitourinary Cancer Symposium: J Clin Oncol 2013; suppl 6:abstract #57
   Google Scholar
• Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987 - 92; http://dx.doi.org/10.1073/pnas.0806075105; PMID: 18818309
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501 - 8; http://dx.doi.org/10.1016/S1470-2045(12)70006-2; PMID: 22326924
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741 - 50; http://dx.doi.org/10.1200/JCO.2005.01.128; PMID: 15613700
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372 - 7; http://dx.doi.org/10.1073/pnas.1533209100; PMID: 12826605
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043 - 53; http://dx.doi.org/10.1200/JCO.2005.06.205; PMID: 16087944
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167 - 75; http://dx.doi.org/10.1200/JCO.2009.26.7609; PMID: 20516446
   PubMed Web of Science ®Google Scholar
• Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol 2010; 2010:237623; http://dx.doi.org/10.1155/2010/237623; PMID: 20617155
   PubMed Web of Science ®Google Scholar
• Schlom J. Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm 2012; 27:2 - 5; http://dx.doi.org/10.1089/cbr.2012.1200; PMID: 22251077
   PubMed Web of Science ®Google Scholar
• Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255 - 66; http://dx.doi.org/10.1586/14760584.6.2.255; PMID: 17408374
   PubMed Web of Science ®Google Scholar
• Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007; 3:e25; http://dx.doi.org/10.1371/journal.ppat.0030025; PMID: 17319743
   PubMedGoogle Scholar
• Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62:5260 - 6; PMID: 12234994
   PubMed Web of Science ®Google Scholar
• Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 2001; 166:731 - 5; PMID: 11145643
   PubMed Web of Science ®Google Scholar
• Lubaroff DM, Konety B, Link BK, Ratliff TL, Madsen T, Shannon M, et al. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther 2006; 17:220 - 9; http://dx.doi.org/10.1089/hum.2006.17.220; PMID: 16454655
   PubMed Web of Science ®Google Scholar
• Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 2012; 11:857 - 68; http://dx.doi.org/10.1586/erv.12.54; PMID: 22913261
   PubMed Web of Science ®Google Scholar
• Lubaroff DM, Williams RD, Vaena D, Joudi F, Brown J, Smith M, et al. An ongoing Phase II trial of an adenovirus/PSA vaccine for prostate cancer. 103rd Annual Meeting of the American Association for Cancer Research. Chicago IL: Cancer Res, 2012.
   Google Scholar
• Ahmad S, Sweeney P, Sullivan GC, Tangney M. DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?. Genet Vaccines Ther 2012; 10:9; http://dx.doi.org/10.1186/1479-0556-10-9; PMID: 23046944
   PubMedGoogle Scholar
• Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639 - 47; http://dx.doi.org/10.1097/CJI.0b013e3181dda23e; PMID: 20551832
   PubMed Web of Science ®Google Scholar
• Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62:217 - 23; http://dx.doi.org/10.1002/pros.20135; PMID: 15389792
   PubMed Web of Science ®Google Scholar
• Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006; 13:320 - 7; http://dx.doi.org/10.1016/j.ymthe.2005.08.005; PMID: 16185933
   PubMed Web of Science ®Google Scholar
• Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978; 253:8721 - 7; PMID: 214430
   PubMed Web of Science ®Google Scholar
• Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7:515 - 23; http://dx.doi.org/10.1089/hum.1996.7.4-515; PMID: 8800746
   PubMed Web of Science ®Google Scholar
• Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274 - 83; PMID: 8221662
   PubMed Web of Science ®Google Scholar
• Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011; 112:1969 - 77; http://dx.doi.org/10.1002/jcb.23126; PMID: 21465529
   PubMed Web of Science ®Google Scholar
• Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 2004; 58:1520 - 9; http://dx.doi.org/10.1016/j.ijrobp.2003.09.083; PMID: 15050332
   PubMed Web of Science ®Google Scholar
• Senovilla L, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: DNA vaccines for cancer therapy. OncoImmunology 2013; 2:e23803; http://dx.doi.org/10.4161/onci.23803
   PubMed Web of Science ®Google Scholar
• Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys 2001; 51:605 - 13; http://dx.doi.org/10.1016/S0360-3016(01)01692-3; PMID: 11597799
   PubMed Web of Science ®Google Scholar